abhishreshthaa
Abhijeet S
SWOT ANALYSIS ON Pfizer : Pfizer Incorporated (NYSE: PFE) is a pharmaceutical company, ranking number one in sales in the world. The company is based in New York City, with its research headquarters in Groton, Connecticut. It produces Lipitor (atorvastatin, used to lower blood cholesterol); the neuropathic pain/fibromyalgia drug Lyrica (pregabalin); the oral antifungal medication Diflucan (fluconazole), the antibiotic Zithromax (azithromycin), Viagra (sildenafil) for erectile dysfunction, and the anti-inflammatory Celebrex (celecoxib) (also known as Celebra in some countries outside the USA and Canada, mainly in South America). Its headquarters are in Midtown Manhattan, New York City.
Pfizer's shares were made a component of the Dow Jones Industrial Average on April 8, 2004.
Pfizer pleaded guilty in 2009 to the largest health care fraud in U.S. history and received the largest criminal penalty ever levied for illegal marketing of four of its drugs. Called a repeat offender, this was Pfizer's fourth such settlement with the U.S. Department of Justice in the previous ten years. On January 26, 2009, Pfizer agreed to buy pharmaceutical giant Wyeth for US$68 billion, a deal financed with cash, shares and loans. The deal was completed on October 15, 2009
Strengths
Pfizer's shares were made a component of the Dow Jones Industrial Average on April 8, 2004.
Pfizer pleaded guilty in 2009 to the largest health care fraud in U.S. history and received the largest criminal penalty ever levied for illegal marketing of four of its drugs. Called a repeat offender, this was Pfizer's fourth such settlement with the U.S. Department of Justice in the previous ten years. On January 26, 2009, Pfizer agreed to buy pharmaceutical giant Wyeth for US$68 billion, a deal financed with cash, shares and loans. The deal was completed on October 15, 2009
Strengths
- Industry leaders
- Strong sales and marketing infrastructure
- Revived blockbuster credentials in recent years - Lyrica, Sutent and Chantix/Champix
- Strong R&D departments
- R&D innovation with a broad therapeutic coverage
- Marketing strength in major geographical and therapeutic areas
- Existing Patent protection for a number of years on key products
jews
Weaknesses
* Drought in blockbuster launches between
1999 and 2004 (masked by M&A activity)
* Entrenchment in low growth therapy area
markets such as CV and CNS
* Very limited penetration of biologics market
* Discontinuation of products in the latter stages of development
* Co-marketing agreements can limit Pfizer's global presence
Opportunities
* Restructuring strategy designed to cut costs and create a leaner company
* Funding available to facilitate product/company
* Acquisitions and in-licensing/co- development opportunities
* Biologic market expansion
* Decreasing development time through favorable R&D collaborations and internal efforts
* Emergence of integrated global markets and globalisation for new products
* Co-marketing agreements with companies wishing to capitalize on Pfizer's marketing
* Strengths, providing Pfizer with strong products and therefore revenue growth
Threats
* Considerable exposure to generic competition, focal point of which is Lipitor, due to lose patent exclusivity in 2011
* Further large scale M&A activity could further decline Pfizer's profitability
* Increased competition for core products like Viagra as its high cost encourages use of cheaper alternative treatments
* An increase in the number of safety issues surrounding Viagra
* Competition from products similar to Pfizer's in R&D that reach the market close to or before Pfizer's products
* The new economic potential of emergent China, India and competition in diverse regional markets.
* Economic downturn influencing consumers' purchasing power
* Negative publicity
Last edited by a moderator: